Prepregnancy GLP-1RA Exposure and Risk of Hypertensive Disorders of Pregnancy Among Women With Obesity and Diabetes
Prepregnancy GLP-1 use showed associations with higher preeclampsia risk in women with obesity and diabetes—a signal warranting larger prospective study.
This small propensity-matched EHR study (n=31 exposed, n=29 controls) found prepregnancy GLP-1RA use was associated with higher preeclampsia risk and cesarean delivery in women with obesity and diabetes. The tiny sample size and observational design limit conclusions, but the safety signal in a growing clinical scenario (GLP-1RA use in reproductive-age women) warrants larger prospective investigation.
What the study was
- Study design
- Retrospective propensity-matched cohort study (EHR data)
- Population
- Pregnant women with obesity and diabetes, prepregnancy GLP-1RA exposure (n=31 exposed, matched n=29)
- Sample size
- 60
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- Obesity
Why it surfaced
Important safety signal for GLP-1RA use in pregnancy-capable women with obesity/diabetes. Very small n=60 matched sample; hypothesis-generating only. Design quality 0 (retrospective, very small). Clinically relevant given widespread GLP-1RA prescription.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.